Tirzepatide vs Semaglutide: Head-to-Head Comparison for Weight Loss

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

The SURMOUNT-5 trial showed tirzepatide produces 47% more weight loss than semaglutide (20.2% vs 13.7% body weight). Tirzepatide's dual GIP+GLP-1 mechanism appears superior to GLP-1 alone. Both have similar GI side effect profiles. Tirzepatide is preferred when maximum weight loss is the goal.

The Head-to-Head Evidence

For years, the comparison between tirzepatide and semaglutide relied on indirect comparisons between separate clinical trials. The SURMOUNT-5 trial, published in 2024, provided the first direct head-to-head comparison of tirzepatide (10 mg or 15 mg weekly) versus semaglutide (2.4 mg weekly) for weight management in adults with obesity. The results were decisive: tirzepatide produced 20.2% weight loss compared to 13.7% with semaglutide — a 47% relative difference.

Why Tirzepatide Is More Effective

Tirzepatide is a dual agonist of both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, and its receptor is expressed in adipose tissue, brain, and pancreas. The combination of GLP-1 and GIP receptor activation appears to produce synergistic effects on appetite suppression, energy expenditure, and fat metabolism that exceed what GLP-1 agonism alone can achieve.

Side Effect Comparison

Both medications share a similar GI side effect profile — nausea, vomiting, diarrhea, and constipation — as both activate GLP-1 receptors in the GI tract. The frequency and severity of GI side effects are comparable between the two medications. Tirzepatide may have a slightly lower rate of nausea at equivalent weight loss efficacy, though this is not definitively established.

Cost and Access Considerations

Both tirzepatide and semaglutide are expensive without insurance coverage ($900–$1,300+ per month). Tirzepatide (Zepbound) is FDA-approved for weight loss, as is semaglutide (Wegovy). Insurance coverage varies significantly. Compounded versions of both medications are available at lower cost, though regulatory status varies.

Choosing Between Them

Choose tirzepatide when: maximum weight loss is the primary goal, the patient has not achieved adequate weight loss on semaglutide, or the patient has type 2 diabetes (tirzepatide has superior glycemic control). Choose semaglutide when: tirzepatide is not available or affordable, the patient has a history of good response to semaglutide, or the patient prefers a medication with a longer track record.